Pfizer Survey Shows Patients Still Want More from Treatment
Hemophilia patients are generally satisfied with their treatment but are more than willing to try something better. That’s the consensus from a recent survey by Pfizer and the Harris Poll. According to the global survey of 1,000 people with hemophilia, 84 % of those asked said they were either somewhat or very satisfied with their […]
Gene Therapy Remains Top of Mind for Hematologists
While the market for hemophilia gene therapy has shrunk in 2026, desire for the treatment remains high. That’s according to a new study from Spherix Global Insights. In a press release issued August 16, the Pennsylvania-based company said their recent survey of European Hematologists showed roughly 90 % of the doctors surveyed expect gene therapies […]
MASAC Announces First-Ever Recommendations for Routine Iron Screening in People with Bleeding Disorders
The following is an announcement from the Medical and Scientific Advisory Council (MASAC). Read the full recommendation here. Iron deficiency, with and without anemia, is the most common micronutrient deficiency around the world. People with bleeding disorders have a higher risk of developing these conditions due to blood loss from bleeding episodes. Until now, there […]
FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations
The following is an announcement from Pfizer: NEW YORK — On June 8 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 […]
Incyte Acquires Vega Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
The following is an announcement from Incyte: WILMINGTON, Del.— Incyte announced on June 8 that it has entered into an agreement to acquire Vega Therapeutics Inc., a wholly owned subsidiary of Star Therapeutics LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones, for total potential consideration of up to $2.0 […]
HFA Joins 47 Other Organizations to Warn of Massive Coverage Losses Under Medicaid Ruling
Below is a sign-on letter Hemophilia Federation of America participated in: Washington, D.C. — On June 3, 48 nonprofit, nonpartisan patient organizations issued a statement in response to the interim final rule implementing the new Medicaid work reporting requirement provisions in Public Law 119-21. “Throughout the legislative process, lawmakers repeatedly promised that the patients […]
Takeda Announces Important Product Supply Update of HEMOFIL and RECOMBINATE
Takeda has announced that as of March 2025, it has decided to globally discontinue HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. This was not a decision made lightly. Takeda understands that this directly impacts patients and they are here to support the hemophilia community during this transition. • […]
Pfizer – Adverse Event in Clinical Trial
Pfizer has announced the death of a participant enrolled in the study of marstacimab in individuals with Hemophilia A or B, on December 14, 2025. Read more
Integration of Spark Therapeutics into the Roche Group and How This Will Affect People With Hemophilia.
Learn more and download the letter to the community.
Product Announcement from Takeda
The Hemophilia Federation of America is writing to share a product announcement from Takeda. Download the Patient Letter from Takeda. Please sign up for the Patient Notification System (PNS) to receive direct notifications about the latest recalls or withdrawals of recombinant and plasma products. HFA will continue to update our community on changes to healthcare […]
English 
Español de Puerto Rico